UBS Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL) as Management Confident in MASH Market Opportunity
Tweet Send to a Friend
UBS analyst Eliana Merle reiterated a Buy rating and $523.00 price target on Madrigal Pharmaceuticals (NASDAQ: MDGL).The analyst commented, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
